StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

BioCryst Pharmaceuticals's pe ratio was 7.6× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20267.6×–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?